Digital health solutions provider makes its ResearchKit and CareKit app
expertise available to research institutions and health companies
worldwide to advance insights into human health
LifeMap Solutions, the digital health subsidiary of BioTime, Inc. (NYSE
MKT: BTX) and co-developer of ResearchKit-enabled app Asthma Health,
today announced a new service to develop custom smartphone apps and
research studies for partners worldwide.
Through the new service, LifeMap offers clients its deep expertise in
medical science, consumer behavior, app analytics, and design. LifeMap
then adds the client’s own unique expertise to the mix and guides the
development, from concept to completion, of a new research or care app
and, optionally, a scientific study.
As the only commercial developer to participate in the launch of Apple’s
ResearchKit, LifeMap Solutions has garnered worldwide attention for
creating engaging, innovative, and data-driven mobile health (mHealth)
apps. LifeMap has worked closely with innovative research institutions
and commercial organizations such as the Icahn School of Medicine at
Mount Sinai, Stanford University School of Medicine, the Mount Sinai –
National Jewish Health Respiratory Institute, and 23andMe.
“The ResearchKit revolution has struck a chord in the scientific and
medical industries,” said Corey Bridges, CEO of LifeMap Solutions.
“Research institutions, hospitals, and multinational pharmaceutical
companies have asked us to help them. They’ve expressed a strong
interest in breaking out of the ‘bricks and mortar’ constraints of
traditional research studies and care tools. For research studies in
particular, the benefits of using mHealth best practices are extremely
compelling: recruiting thousands of study participants nationally or
even internationally, obtaining consent through the friendly interface
of the iPhone, and passively collecting participants’ health
information. We’re entering a new era of accelerated scientific
discovery. And, with Apple’s new CareKit platform, I expect we’ll see a
similar revolution in medical care. Thanks to our team’s unique skillset
and experience, I believe LifeMap Solutions will play a market-leading
role as the mHealth field evolves.”
In building research apps, LifeMap’s new app-design and creation service
follows a simple five-step process. The LifeMap Solutions team works
with partners to:
-
Plan - integrate their design into a secure mHealth platform
and build a fully customized app that satisfies study and consent
requirements, delivered on time and on budget.
-
Review - work with a partner’s Institutional Review Board (IRB)
to facilitate approval of research studies conducted through
smartphones.
-
Build - transform traditional research elements into visually
compelling and engaging apps.
-
Launch - facilitate the app’s launch by working with an
institution’s own app-publishing team or submitting the app directly
into the App Store.
-
Publish - help to best utilize the data to further research and
transform findings into scientific articles and peer-reviewed
publications with a team of highly skilled data scientists.
Organizations interested in working with LifeMap Solutions can learn
more and contact
the company here.
About LifeMap Solutions, Inc.
LifeMap Solutions develops innovative digital health solutions by
integrating health and wellness information with care team guidance into
a secure mHealth platform to deliver digital health solutions that
empower patients to make better choices to achieve optimal health
outcomes. LifeMap Solutions is a subsidiary of BioTime, Inc., and is
headquartered in San Jose, California. For more information, please
visit www.lifemap-solutions.com.
About BioTime
BioTime, Inc. is a clinical-stage biotechnology company focused on
developing and commercializing novel therapies developed from what we
believe to be the world’s premier collection of pluripotent stem cell
assets. The foundation of our core therapeutic technology platform is
pluripotent stem cells that are capable of becoming any of the cell
types in the human body. Pluripotent stem cells have potential
application in many areas of medicine with large unmet patient needs,
including various age-related degenerative diseases and degenerative
conditions for which there presently are no cures. Unlike
pharmaceuticals that require a molecular target, therapeutic strategies
based on the use of pluripotent stem cells are generally aimed at
regenerating or replacing affected cells and tissues, and therefore may
have broader applicability than pharmaceutical products.
Forward-Looking Statements
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as “will,” “believes,”
“plans,” “anticipates,” “expects,” “estimates”) should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime's Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160425005785/en/
Copyright Business Wire 2016